These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Pachman LM; Lipton R; Ramsey-Goldman R; Shamiyeh E; Abbott K; Mendez EP; Dyer A; Curdy DM; Vogler L; Reed A; Cawkwell G; Zemel L; Sandborg C; Rivas-Chacon R; Hom C; Ilowite N; Gedalia A; Gitlin J; Borzy M Arthritis Rheum; 2005 Apr; 53(2):166-72. PubMed ID: 15818654 [TBL] [Abstract][Full Text] [Related]
6. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Sanner H; Gran JT; Sjaastad I; Flatø B Rheumatology (Oxford); 2009 Dec; 48(12):1541-7. PubMed ID: 19776224 [TBL] [Abstract][Full Text] [Related]
7. Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis. Marhaug G; Shah V; Shroff R; Varsani H; Wedderburn LR; Pilkington CA; Brogan PA Rheumatology (Oxford); 2008 Jul; 47(7):1031-7. PubMed ID: 18448482 [TBL] [Abstract][Full Text] [Related]
8. Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores. McCann LJ; Garay SM; Ryan MM; Harris R; Riley P; Pilkington CA Rheumatology (Oxford); 2007 Aug; 46(8):1363-6. PubMed ID: 17569746 [TBL] [Abstract][Full Text] [Related]
9. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304 [TBL] [Abstract][Full Text] [Related]
11. Calcinosis in juvenile dermatomyositis: a possible role for the vitamin K-dependent protein matrix Gla protein. van Summeren MJ; Spliet WG; van Royen-Kerkhof A; Vermeer C; Lilien M; Kuis W; Schurgers LJ Rheumatology (Oxford); 2008 Mar; 47(3):267-71. PubMed ID: 18234711 [TBL] [Abstract][Full Text] [Related]
12. [Multi-center analysis of calcinosis in children with juvenile dermatomyositis]. Miyamae T; Mori M; Inamo Y; Kohno Y; Takei S; Maeda M; Murata T; Nakata S; Kawai H; Hirano Y; Date Y; Kitamura K; Yokota S Ryumachi; 2003 Jun; 43(3):538-43. PubMed ID: 12910962 [TBL] [Abstract][Full Text] [Related]
13. Pathological calcification in juvenile dermatomyositis (JDM): microCT and synchrotron x-ray diffraction reveal hydroxyapatite with varied microstructures. Stock S; Ignatiev K; Lee P; Abbott K; Pachman L Connect Tissue Res; 2004; 45(4-5):248-56. PubMed ID: 15763934 [TBL] [Abstract][Full Text] [Related]
14. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. Sanner H; Sjaastad I; Flatø B Rheumatology (Oxford); 2014 Sep; 53(9):1578-85. PubMed ID: 24692575 [TBL] [Abstract][Full Text] [Related]
15. Fear of harm, a possible phenotype of pediatric bipolar disorder: a dimensional approach to diagnosis for genotyping psychiatric syndromes. Papolos D; Mattis S; Golshan S; Molay F J Affect Disord; 2009 Nov; 118(1-3):28-38. PubMed ID: 19631388 [TBL] [Abstract][Full Text] [Related]
16. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. Smith RL; Sundberg J; Shamiyah E; Dyer A; Pachman LM J Rheumatol; 2004 Aug; 31(8):1644-9. PubMed ID: 15290747 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Riley P; McCann LJ; Maillard SM; Woo P; Murray KJ; Pilkington CA Rheumatology (Oxford); 2008 Jun; 47(6):877-80. PubMed ID: 18403404 [TBL] [Abstract][Full Text] [Related]
18. Clinical assessment in juvenile dermatomyositis. Ravelli A; Ruperto N; Trail L; Felici E; Sala E; Martini A Autoimmunity; 2006 May; 39(3):197-203. PubMed ID: 16769653 [TBL] [Abstract][Full Text] [Related]
19. Juvenile dermatomyositis: extramuscular manifestations and their management. Lowry CA; Pilkington CA Curr Opin Rheumatol; 2009 Nov; 21(6):575-80. PubMed ID: 19730375 [TBL] [Abstract][Full Text] [Related]
20. [Epidemioclinical aspects of dermatomyositis in the region of Tunis]. Khelifa E; Benmously R; Fenniche S; Marrak H; Zghal M; Mokhtar I Tunis Med; 2007 Aug; 85(8):655-8. PubMed ID: 18254286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]